Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study

Adding pembrolizumab to enzalutamide did not improve efficacy outcomes for participants with chemotherapy-naive mCRPC. Additional toxicity was observed with the combination regimen.

Authors

Institutions

Publication Details

Journal
Annals of Oncology
Published
2025-05-16
DOI
https://doi.org/10.1016/j.annonc.2025.05.007
Citations
11
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
16.70

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study

Jorge Salinas, Jóse Ángel Arranz Arija, Li Liang, M. Retz et al.
11 citations
Annals of Oncology
Prostate Cancer Treatment and Research
16.70
article

Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study

Jorge Salinas, Jóse Ángel Arranz Arija, Li Liang, M. Retz, Howard Gurney, Lorea Villanueva, Ray Manneh Kopp, Cheol Kwak, T. Todenhöfer, Gero Kramer, Mauricio Burotto, Jeremy Graff, N. Matsubara, P.C. Fong, Kazuo Imai, B. Zurawski, Arnulf Stenzl, Jelena Todoric, Raffaele Ratta, David Pook, Mariusz Kwiatkowski, Kathryn Bylow
article en
11 citations

Abstract

Adding pembrolizumab to enzalutamide did not improve efficacy outcomes for participants with chemotherapy-naive mCRPC. Additional toxicity was observed with the combination regimen.

Annals of OncologyVol. 36(8)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), University of Auckland (NZ), Oregon Health & Science University (US), Medical College of Wisconsin (US), Fundación Chile (CL), Auckland City Hospital (NZ), TUM Klinikum (DE), Seoul National University Hospital (KR), Hospital General Universitario Gregorio Marañón (ES), Popular University of Cesar (CO), Klinik und Poliklinik für Urologie (DE), Centro de Excelencia en Procesos y Productos de Córdoba (AR), Monash Health (AU), Centrum Onkologii (PL), Fundación Arturo López Pérez (CL), Wojewódzki Szpital Zespolony (PL), National Cancer Center Hospital East (JP), Hôpital Foch (FR), Medical University of Vienna (AT), Macquarie University (AU)
Merck Sharp and Dohme
Good health and well-being
Openalex Percentile: Top 1%
Prostate Cancer Treatment and Research
16.70
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.